Nuvectis Pharma, Inc.
NVCT
$18.96
-$0.27-1.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.22% | 36.80% | 35.96% | 16.71% | 8.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.67% | 34.48% | 38.93% | 37.07% | 9.06% |
| Operating Income | -25.67% | -34.48% | -38.93% | -37.07% | -9.06% |
| Income Before Tax | -26.19% | -34.72% | -39.17% | -30.98% | -4.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.19% | -34.72% | -39.17% | -30.98% | -4.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.19% | -34.72% | -39.17% | -30.98% | -4.57% |
| EBIT | -25.67% | -34.48% | -38.93% | -37.07% | -9.06% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -13.10% | -16.33% | -18.78% | -16.11% | 10.19% |
| Normalized Basic EPS | -3.86% | -6.81% | -9.12% | -12.91% | 5.66% |
| EPS Diluted | -13.10% | -16.33% | -18.78% | -16.11% | 10.19% |
| Normalized Diluted EPS | -3.86% | -6.81% | -9.12% | -12.91% | 5.66% |
| Average Basic Shares Outstanding | 21.65% | 26.27% | 27.42% | 22.26% | 16.01% |
| Average Diluted Shares Outstanding | 21.65% | 26.27% | 27.42% | 22.26% | 16.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |